Identification of serum proteome signature of irritable bowel syndrome: Potential utility of the tool for early diagnosis and patient's stratification

Tsigaridas, Athanasios; Anagnostopoulos, Athanasios K.; Papadopoulou, Aggeliki; Ioakeim, Stamatia; Vaiopoulou, Anna; Papanikolaou, Ioannis S.; Viazis, Nikos; Karamanolis, George; Mantzaris, Gerasimos; Tsangaris, George Th.; Gazouli, Maria

doi:10.1016/j.jprot.2017.07.019

Cited by 12 publications

(9 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increased humoral immunity in the jejunum of IBS patients was observed, showing a closer distance between mast cells and plasma cells in the mucosa (152). Changes in proteomic signatures have been also described in the colonic mucosa of experimental models of IBS (44,97) and, more recently, in urine (59), serum (147,160), and the small intestinal mucosa of IBS patients (127) (Table 2). However, high-throughput techniques applied in those studies are not able to reflect posttranslational events modulating protein activity, like imbalanced protein degradation rates, phosphorylation, and subcellular mislocalization.…”

Section: Transcriptomic and Proteomic Analysis In The Small Bowel Of Ibs Patientsmentioning

confidence: 91%

Mucosal RNA and protein expression as the next frontier in IBS: abnormal function despite morphologically intact small intestinal mucosa

Rodiño-Janeiro

Pardo-Camacho

Santos

et al. 2019

American Journal of Physiology-Gastrointestinal and Liver Physi

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is one of the commonest gastrointestinal disorders. Although long-time considered a pure functional disorder, intense research in past years has rendered a very complex and varied array of observations indicating the presence of structural and molecular abnormalities underlying characteristic motor and sensitive changes and clinical manifestations. Analysis of gene and protein expression in the intestinal mucosa has shed light on the molecular mechanisms implicated in IBS physiopathology. This analysis uncovers constitutive and inductive genetic and epigenetic marks in the small and large intestine that highlight the role of epithelial barrier, immune activation, and mucosal processing of foods and toxins and several new molecular pathways in the origin of IBS. The incorporation of innovative high-throughput techniques into IBS research is beginning to provide new insights into highly structured and interconnected molecular mechanisms modulating gene and protein expression at tissue level. Integration and correlation of these molecular mechanisms with clinical and environmental data applying systems biology/medicine and data mining tools emerge as crucial steps that will allow us to get meaningful and more definitive comprehension of IBS-detailed development and show the real mechanisms and causality of the disease and the way to identify more specific diagnostic biomarkers and effective treatments.

show abstract

Section: Transcriptomic and Proteomic Analysis In The Small Bowel Of Ibs Patientsmentioning

confidence: 91%

Mucosal RNA and protein expression as the next frontier in IBS: abnormal function despite morphologically intact small intestinal mucosa

Rodiño-Janeiro

Pardo-Camacho

Santos

et al. 2019

American Journal of Physiology-Gastrointestinal and Liver Physi

View full text Add to dashboard Cite

show abstract

“… 24 Athanasios Tsigaridas et al performed proteomic analysis on serum samples of 30 irritable bowel syndrome patients and 10 healthy individuals, identifying eight differentially expressed proteins, including APOE, a polymorphic protein; in subgroup analysis, it was found that APOE was highly expressed in the diarrhea group. 25 Ryotaro Ogawa et al found that CXCL8 correlates highly with angiogenesis and progression of colorectal cancer. High expression of CXCL8 in colorectal cancer leads to a very poor prognosis and promotes liver metastasis.…”

Section: Discussionmentioning

confidence: 99%

Analysis of Key Genes for Slow Transit Constipation Based on RNA Sequencing

Yu¹,

Yang²,

Guan³

et al. 2022

IJGM

View full text Add to dashboard Cite

This study aims to identify key genes in slow transit constipation (STC). We also sought to explore the potential link between STC and colorectal cancer. Patients and Methods: mRNA expression profiles were obtained by RNA sequencing, and differentially expressed genes were identified. Functional enrichment analysis and a protein-protein interaction (PPI) network was explored, and differentially expressed genes common to STC and colorectal cancer were examined. Analysis of the effect of constipation and colorectal cancer common genes on the overall survival of colorectal cancer patients based on GEPIA database. Results: Functional enrichment showed that significantly different genes are related to lymphocyte chemotaxis, positive regulation of inflammatory response, cellular response to tumor necrosis factor, extracellular region, extracellular space and chemokine activity. The hub gene for STC was found in the PPI network. In addition, AQP8 and CFD were common differential genes for STC and colorectal cancer. AQP8 affects overall survival in patients with colorectal cancer. Conclusion: Our findings will contribute to understanding the pathology of STC at the molecular level, with the first discovery that AQP8 may be a hub gene in the transition from STC to colorectal cancer.

show abstract

“…In addition to systemic inflammation biomarkers and intestinal mucosal expression of RNA about inflammatory cytokines (Aerssens et al, 2008;Swan et al, 2013), many studies focused on differently expressed proteins in serum samples between IBS patients and healthy controls by mass spectrometry. (Tsigaridas et al, 2018;Weaver et al, 2018) Previous studies identified 8 differently expressed proteins (IGKC, LAC3, APOE, CLUS, TRFE, APOH, XIV and COEA1) between IBS patients (n = 30) and healthy individuals (n = 10). (Tsigaridas et al, 2018) Another study by Kristen et al found TGFβ1, PF4V1, PF4, APP, MMP9, PPBP, CTGF, SRGN, THBS1, WRN, LTBP1 (Isoform 3), and IGLV5-48 were significantly different in levels of expression of serum samples Frontiers in Physiology frontiersin.org 10 between IBS-C patients and healthy controls (n = 5 in each group).…”

Section: Discussionmentioning

confidence: 99%

“…(Tsigaridas et al, 2018;Weaver et al, 2018) Previous studies identified 8 differently expressed proteins (IGKC, LAC3, APOE, CLUS, TRFE, APOH, XIV and COEA1) between IBS patients (n = 30) and healthy individuals (n = 10). (Tsigaridas et al, 2018) Another study by Kristen et al found TGFβ1, PF4V1, PF4, APP, MMP9, PPBP, CTGF, SRGN, THBS1, WRN, LTBP1 (Isoform 3), and IGLV5-48 were significantly different in levels of expression of serum samples Frontiers in Physiology frontiersin.org 10 between IBS-C patients and healthy controls (n = 5 in each group). (Weaver et al, 2018) However, these results were obtained from smaller samples and the method of mass spectrometry covered limited proteins.…”

Section: Discussionmentioning

confidence: 99%

Multiple rather than specific autoantibodies were identified in irritable bowel syndrome with HuProt™ proteome microarray

Fan

Fang

et al. 2022

Front. Physiol.

View full text Add to dashboard Cite

Immune activation and several autoantibodies might be involved in the pathophysiology of irritable bowel syndrome (IBS). We aimed to identify serum biomarkers for IBS by HuProt™ microarray. IBS patients met Rome III criteria were enrolled. Control groups included healthy controls (HCs) and disease controls (DCs). In stage I, we profiled sera from IBS and control groups with HuProt™ microarrays. Based on significant different proteins in stage I, IBS focused microarrays were constructed and validated in a larger cohort in stage II, then decision tree models were generated to establish a combination of biomarkers. In stage III, 4 purified proteins were verified by ELISA. Finally, we analyzed the correlation of autoantibodies with symptoms. In stage I, we identified 47 significant different proteins including 8 autoantibodies of IgG, 2 of IgA between IBS and HCs; 13 autoantibodies of IgG, 13 of IgA between IBS and DCs. In stage II, we found the positive rates of 14 IgG and IgA autoantibodies in IBS were significantly higher than HCs. Five autoantibodies of IgG and 7 IgA were comprehensively involved in differentiating IBS and HCs with the sensitivity and specificity to diagnose IBS as 40%–46.7% and 79.4%–86.3%. The median optical density value of ELAVL4 (IgG) and PIGP (IgA) were significantly higher in IBS than HCs. Parts of autoantibodies above were related to IBS symptoms. We found a combination of autoantibodies to differentiate IBS with HCs, but no specific autoantibodies could serve as serum biomarkers for IBS.

show abstract

Identification of serum proteome signature of irritable bowel syndrome: Potential utility of the tool for early diagnosis and patient's stratification

Cited by 12 publications

References 58 publications

Mucosal RNA and protein expression as the next frontier in IBS: abnormal function despite morphologically intact small intestinal mucosa

Mucosal RNA and protein expression as the next frontier in IBS: abnormal function despite morphologically intact small intestinal mucosa

Analysis of Key Genes for Slow Transit Constipation Based on RNA Sequencing

Multiple rather than specific autoantibodies were identified in irritable bowel syndrome with HuProt™ proteome microarray

Contact Info

Product

Resources

About